DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely explain the development of narrowing within the heart arteries which can subsequently produce symptoms of angina (chest pain).

Previous research has shown a specialised scanner known as a PET (positron emission tomography) scan can identify these recently ruptured plaques in patients without symptoms of a heart attack and these patients have changes on a blood test (troponin) which suggest that they are at higher risk of having a heart attack in the future. This study aims to identify these patients using the PET scan and then see if the markers of increased heart attack risk can be reduced by the use of a blood thinning medication (ticagrelor) which is already a well recognised treatment for people who have suffered a recent heart attack.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

NCT01731041

Coronary Artery Disease

COMPLETED NA

Ticagrelor China Pharmacokinetic/Pharmacodynamic Study

NCT02064985

Stable Coronary Heart Disease (CHD)

COMPLETED PHASE4

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

NCT04069234

Diabetes Mellitus Microvascular Coronary Artery Disease

WITHDRAWN PHASE3

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

NCT01595854

Healthy

COMPLETED PHASE1

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

NCT04999293

Platelet Aggregation Inhibitors Dual Anti-Platelet Therapy Aged +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim to recruit patients with multivessel, clinically stable coronary artery disease. Patients will undergo baseline investigations including CT-PET imaging using 18F-Sodium Fluoride (18F-F) tracer to detect potentially unstable coronary plaques. The groups will be separated into those with and without 18F-F uptake. Each of these groups will be randomised to receive oral ticagrelor or a matched placebo in addition to their usual medications. Patients will remain on aspirin but will not be eligible for the trial if taking additional antiplatelet/anticoagulant treatments. The treatment will be continued for 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18F-F Positive - Ticagrelor

Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

oral, 90mg tablets, twice daily, 12 month duration

18F-F Positive - Placebo

Identical placebo, one tablet, twice daily, 12 month duration

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral tablet (identical to ticagrelor), twice daily, 12 month duration

18F-F Negative - Ticagrelor

Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration

Group Type EXPERIMENTAL

Ticagrelor

Intervention Type DRUG

oral, 90mg tablets, twice daily, 12 month duration

18F-F Negative - Placebo

Identical placebo, one tablet, twice daily, 12 month duration

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral tablet (identical to ticagrelor), twice daily, 12 month duration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ticagrelor

oral, 90mg tablets, twice daily, 12 month duration

Intervention Type DRUG

Placebo

Oral tablet (identical to ticagrelor), twice daily, 12 month duration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brilique Brilinta Possia AZD6140 SUB30898 B01AC24

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged ≥40 years with angiographically proven multivessel coronary artery disease defined as at least two major epicardial vessels with any combination of either (a) \>50% luminal stenosis, or (b) previous revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).
* Provision of informed consent prior to any study specific procedures

Exclusion Criteria

* An acute coronary syndrome within the last 12 months
* An indication for dual anti-platelet therapy, such as drug eluting stent
* Inability to take aspirin
* Receiving thienopyridine therapy such as clopidogrel or prasugrel
* Percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 months
* Inability or unwilling to give informed consent
* Woman with child-bearing potential and who are breastfeeding will not be enrolled into the trial (woman who have experienced menarche, are pre-menopausal, have not been sterilised or who are currently pregnant)
* Known hypersensitivity to ticagrelor or one of its excipients
* Active pathological bleeding or bleeding diathesis
* Significant thrombocytopenia: \<100 x 10\^9 /L
* History of intracranial haemorrhage
* Moderate to severe liver impairment (Child's Grade B or C)
* Maintenance therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors, such as ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin
* Major intercurrent illness or life expectancy \<1 year
* Renal dysfunction (eGFR ≤30 mL/min/1.73 m2)
* Contraindication to iodinated contrast agents
* Planned coronary revascularization or major non-cardiac surgery in the next 12 months
* Maintenance therapy with simvastatin at doses greater than 40mg daily
* Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No